Eli Lilly: A Pharmaceutical Juggernaut That Just Crushed Earnings Estimates

Many have said that pharmaceutical companies would be a logical place to invest if the rest of the market began to slow down. They may have been onto something. Eli Lilly & Co. reported Q2 earnings and revenue that crushed expectations.